EWEric C. Wang

Eric C. Wang

*This is an algorithmically generated author record based on publicly available information.

Eric C. Wang has a total of 9 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Asymmetric Synthesis of the TRPV1 Modulator AMG8562 via Lipase-Catalyzed Kinetic Resolution

    by Eric C. Wang, Pyeonghwa Jeong, Chris Han, Yunju Oh, Yiquan Zhao, Jiyong Hong

    The transient receptor potential vanilloid-1 (TRPV1) channel is a key mediator of pain perception and responds to various stimuli such as heat, low pH, and inflammation. Among TRPV1 antagonists, (R,E)-N-(2-hydroxy-2,3-dihydro-1H-inden-4-yl)-3-(2-(piperidin-1-yl)-4-(trifluoromethyl)-phenyl)-acrylamide (AMG8562) shows promise as a nonopioid analgesic, attenuating pain behaviors in rodent models without eliciting hyperthermic side effects commonly associated with other TRPV1 antagonists. Despite its potential, there has been limited research regarding the synthesis of AMG8562. Here, we present an asymmetric synthesis of AMG8562 featuring a lipase-catalyzed kinetic resolution of racemic 4-nitroindan-2-ol. This approach enables scalable access to enantiomerically pure material and provides a platform for the synthesis of structurally diverse AMG8562 analogues with potential for improved pharmacological properties.

  • Asymmetric Total Synthesis of Daucane-Type Sesquiterpenoids (+)-Ferutinin and (+)-Kuhistanicaol G

    by Yiquan Zhao, Eric C. Wang, Jinjae Park, Iljin Shin, Hyoungsu Kim, Jiyong Hong

    Given the poor outcomes associated with current pancreatic cancer therapies, the "antiausterity" activity of ferutinin and kuhistanicaol G is particularly encouraging. The asymmetric syntheses of (+)-ferutinin and (+)-kuhistanicaol G are achieved through a sequence involving tandem radical addition/allylation, chelation-controlled nucleophilic addition, and Chugaev elimination. This synthetic strategy enables the efficient construction of appropriately functionalized 5,7-fused daucane skeletons. Our work paves the way for the development of new pancreatic cancer therapeutics and provides access to chemical probes for elucidating mechanisms of action.